Why technical aspects rather than biology explain cellular heterogeneity in ALK-positive non-small cell lung cancer

Journal of Thoracic Disease

Volumn 4, Issue 3, 2012, Pages 240-241

  McLeer Florin, Anne ^a,b   Lantuéjoul, Sylvie ^c,d  

^a HÔPITAL MICHALLON   (France)

^b CEA GRENOBLE   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CHIMERIC PROTEIN; CRIZOTINIB;

ARTICLE; CELL ACTIVATION; CELL HETEROGENEITY; CELLULAR DISTRIBUTION; CHROMOSOME 2; DIMERIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; OLIGOMERIZATION; SMOKING; TREATMENT RESPONSE; TUMOR CELL;

EID: 84864439345     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.06.05     Document Type: Article

References (7)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
2. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 2008;99:2349-55.
3. Takeuchi K, Choi YL, Togashi Y, et al. K1F5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-9.
4. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203.
5. Togashi Y, Soda M, Sakata S, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012;7:e31323.
6. Camidge DR, Tneodoro M, Maxson DA, et al. Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 2012. [Epub ahead of print].
7. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16:5581-90.